Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Expanded_access × lazertinib × Thoracic × Clear all

Status

Approved for marketing 1

Sponsor Class

Study Type

Interventional 17 Observational 3 Expanded_access 1

Sponsor

Cancer Type

Conditions

Lung Neoplasms 1

Interventions

Afatinib 3 ceritinib 2 Gefitinib 2 zenocutuzumab 1 ulixertinib 1 trilaciclib 1 telisotuzumab vedotin 1 tazemetostat 1 taletrectinib 1 selpercatinib 1 rovalpituzumab tesirine 1 rociletinib 1 pegilodecakin 1 patritumab deruxtecan 1 osimertinib 1 mobocertinib 1 lorlatinib 1 lazertinib 1 epigallocatechin gallate 1 ensartinib 1 dabrafenib 1 cemiplimab 1 capmatinib 1 brigatinib 1 balstilimab 1 alectinib 1 Suspensions 1 Powders 1 Pemetrexed 1 Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04829422 2022-03-03

Early Access Program of Lazertinib in Republic of Korea

Yuhan Corporation

Approved for marketing

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡